tirzepatide for iih Trial Idiopathic Intracranial Hypertension | University of Birmingham posted on the topic tirzepatide for iih Tirzepatide Trial

In clinical studies, people who were prescribed Wegovy lost around 15% of their body weight on average over 68 weeks (slightly over 16 months), compared to only 2-3% in people who didnt take it

You can not dose at 0.75 mg or 1.5 mg or any amount between the fixed stops

[1] The FDA label includes a boxed warning regarding thyroid C-cell tumors and contraindicates tirzepatide in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

Alam J, Cook JL (2003) Transcriptional regulation of the heme oxygenase-1 gene via the stress response element pathway

If you have patience, the side effects can get better